中生方政NBF品牌怎么样 申请店铺

我要投票 中生方政NBF在医疗器械行业中的票数:158 更新时间:2025-04-03
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!通过在本页面挂载中生方政NBF品牌的产品链接和联系邮箱,可以提高中生方政NBF产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

证监会:进一步完善全链条全生命周期的多层次市场服务体系,加力支持优质民营企业做强做优做大

36氪获悉,证监会召开深化资本市场投融资综合改革民营科技企业座谈会。吴清强调,民营经济是国民经济的重要组成部分,是推动科技创新的重要力量。大力支持民营经济发展,既是资本市场服务实体经济的内在要求,也是加快培育高质量上市公司和促进资本市场高质量发展的重要着力点。尊重市场规律,切实提升资本市场的包容性、适应性,持续增强规则的透明度、可预期性,进一步完善全链条全生命周期的多层次市场服务体系,加力支持优质民营企业做强做优做大。

2小时前

吴清:民营科技企业作为民营经济和新质生产力领域的优秀代表,希望大家坚定信心,保持爱拼才会赢的精气神

证监会党委书记、主席吴清在北京召开专题座谈会,与集成电路、新能源汽车、智能制造、新材料、商业航天、网络经济等不同领域的民营科技企业代表深入交流。吴清强调,进一步完善全链条全生命周期的多层次市场服务体系,加力支持优质民营企业做强做优做大。民营科技企业作为民营经济和新质生产力领域的优秀代表,希望大家坚定信心,保持爱拼才会赢的精气神,以实际行动发挥好示范带头作用,积极利用资本市场转型升级、做优做强,更好回报投资者,为推动经济高质量发展和中国式现代化积极贡献力量。

2小时前

广汽集团:3月汽车销量173929辆,同比下降3.01%

36氪获悉,广汽集团公告,3月汽车销量173929辆,同比下降3.01%。其中新能源汽车销量33362辆,同比下降0.72%。

2小时前

盈富基金获南向资金净买入60.72亿港元

南向资金大幅净买入287.9亿港元,盈富基金、恒生中国企业、阿里巴巴-W分别获净买入60.72亿港元、48.33亿港元、34.87亿港元;申洲国际净卖出额居首,金额为0.12亿港元。(第一财经)

2小时前

保诚委任新区域执行总裁

保诚(Prudential)4月3日宣布,将委任蔡强为区域执行总裁,负责马来西亚、印尼及越南和代理人销售事务。现任区域执行总裁(高增长市场、健康保险及代理人销售)索尔马兹‧阿尔丁(Solmaz Altin)决定返回欧洲。蔡强将加入集团行政委员会,并常驻香港及向执行总裁华康尧(Anil Wadhwani)汇报,委任将于四月七日生效。(界面)

2小时前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询